Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Zura Bio Limited (NASDAQ:ZURA) has received a consensus rating of "Moderate Buy" from analysts, with one sell, one hold, five buy, and one strong buy ratings.
• The average one-year price target among brokerages for Zura Bio is $11.60, reflecting varying outlooks from different analysts.
• The company reported a quarterly EPS of (0.17), better than the consensus estimate of (0.19), indicating a slight improvement in financial performance.

Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $11.60.

A number of research firms have recently commented on ZURA. Chardan Capital reaffirmed a "buy" rating and issued a $10.00 price target on shares of Zura Bio in a report on Tuesday, September 30th. HC Wainwright cut their price target on Zura Bio from $3.00 to $2.00 and set a "neutral" rating for the company in a report on Tuesday, August 19th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Zura Bio in a report on Tuesday, October 14th. Finally, Oppenheimer cut their price target on Zura Bio from $17.00 to $16.00 and set an "outperform" rating for the company in a report on Friday, August 15th.

Zura Bio Price Performance

Shares of ZURA stock opened at $3.37 on Tuesday. The stock has a market capitalization of $219.12 million, a price-to-earnings ratio of -4.81 and a beta of 0.25. The company's fifty day simple moving average is $2.59 and its two-hundred day simple moving average is $1.73. Zura Bio has a 1 year low of $0.97 and a 1 year high of $4.98.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. Equities research analysts anticipate that Zura Bio will post -0.65 EPS for the current year.

Institutional Investors Weigh In On Zura Bio

Several large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its stake in Zura Bio by 31.9% during the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company's stock valued at $103,000 after buying an additional 9,966 shares during the period. Savant Capital LLC boosted its stake in Zura Bio by 190.4% during the second quarter. Savant Capital LLC now owns 32,409 shares of the company's stock valued at $34,000 after buying an additional 21,249 shares during the period. Forefront Wealth Partners LLC bought a new stake in Zura Bio during the third quarter valued at $93,000. Armistice Capital LLC boosted its stake in Zura Bio by 2.4% during the first quarter. Armistice Capital LLC now owns 1,536,000 shares of the company's stock valued at $1,981,000 after buying an additional 36,000 shares during the period. Finally, Forefront Analytics LLC boosted its stake in Zura Bio by 101.6% during the first quarter. Forefront Analytics LLC now owns 108,308 shares of the company's stock valued at $140,000 after buying an additional 54,574 shares during the period. Institutional investors own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.